InsiderTrades.com logo
James M. Frates net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

James Frates Biography and Net Worth

CFO of Amylyx Pharmaceuticals

Jim Frates serves as Amylyx’s Chief Financial Officer, having previously been the CFO of Alkermes for 22 years. Prior to working at Alkermes, Jim was a Vice President in the Life Sciences Practice at Robertson Stephens & Company. He currently serves on the board of directors of Sage Therapeutics and is a Trustee of St. Francis House, the largest homeless day shelter in Massachusetts. Jim earned a Bachelor of Arts in Government from Harvard College and a Master of Business Administration from the Harvard Graduate School of Business Administration.

What is James M. Frates' net worth?

The estimated net worth of James M. Frates is at least $2.52 million as of January 6th, 2026. Frates owns 177,104 shares of Amylyx Pharmaceuticals stock worth more than $2,518,419 as of February 9th. This net worth evaluation does not reflect any other investments that Frates may own. Additionally, Frates receives a salary of $763,160.00 as CFO at Amylyx Pharmaceuticals. Learn More about James M. Frates' net worth.

How old is James M. Frates?

Frates is currently 57 years old. There are 4 older executives and no younger executives at Amylyx Pharmaceuticals. The oldest executive at Amylyx Pharmaceuticals is Dr. Camille L. Bedrosian M.D., Chief Medical Officer, who is 71 years old. Learn More on James M. Frates' age.

What is James M. Frates' salary?

As the CFO of Amylyx Pharmaceuticals, Inc., Frates earns $763,160.00 per year. There are 2 executives that earn more than Frates. The highest earning executive at Amylyx Pharmaceuticals is Mr. Joshua B. Cohen, Co-Founder, Co-CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on James M. Frates' salary.

How do I contact James M. Frates?

The corporate mailing address for Frates and other Amylyx Pharmaceuticals executives is , , . Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on James M. Frates' contact information.

Has James M. Frates been buying or selling shares of Amylyx Pharmaceuticals?

In the last ninety days, James M. Frates has sold $36,951.86 of Amylyx Pharmaceuticals stock. Most recently, James M. Frates sold 3,326 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $11.11, for a transaction totalling $36,951.86. Following the completion of the sale, the chief financial officer now directly owns 177,104 shares of the company's stock, valued at $1,967,625.44. Learn More on James M. Frates' trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), Karen Firestone (Director), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 2 times. They purchased a total of 18,100 shares worth more than $137,845.00. In the last year, insiders at the sold shares 15 times. They sold a total of 298,096 shares worth more than $3,610,929.18. The most recent insider tranaction occured on January, 16th when CEO Joshua B Cohen sold 1,974 shares worth more than $27,300.42. Insiders at Amylyx Pharmaceuticals own 12.3% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 1/16/2026.

James M. Frates Insider Trading History at Amylyx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/6/2026Sell3,326$11.11$36,951.86177,104View SEC Filing Icon  
9/30/2025Sell10,558$14.65$154,674.70280,430View SEC Filing Icon  
3/31/2025Sell10,896$3.47$37,809.12290,988View SEC Filing Icon  
9/12/2024Buy40,000$2.53$101,200.00233,464View SEC Filing Icon  
3/5/2024Sell1,792$18.73$33,564.16134,784View SEC Filing Icon  
1/9/2024Sell2,716$16.33$44,352.28112,035View SEC Filing Icon  
5/16/2023Sell32,500$26.94$875,550.0055,676View SEC Filing Icon  
3/16/2023Sell32,500$31.89$1,036,425.001,509View SEC Filing Icon  
See Full Table

James M. Frates Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows James M Frates's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.22
Low: $13.58
High: $14.25

50 Day Range

MA: $13.38
Low: $11.38
High: $16.92

2 Week Range

Now: $14.22
Low: $2.60
High: $17.49

Volume

494,888 shs

Average Volume

1,644,704 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A